TEL: 044-952-0102


Opioids Market Overview to 2023 - Opioids in Western Europe

発行 CBR Pharma Insights 商品コード 318490
出版日 ページ情報 英文 74 Pages
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: CBR Pharma Insights社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
オピオイド市場の将来展望:西欧におけるオピオイド市場 Opioids Market Overview to 2023 - Opioids in Western Europe
出版日: 2014年10月31日 ページ情報: 英文 74 Pages





  • 疼痛管理におけるオピオイド
  • 使用制限
  • 国際会議


  • 薬物誤用の広がり
  • 乱用抑制薬の影響
  • 主な乱用抑制製品


  • 必要条件と消費動向
  • 利用促進のための主な活動


  • 入手可能性と使用規制との間のバランスの釣り合い


  • 欧州域内の消費動向
  • 市場収益額の推定値・予測値


  • 規制情勢
  • 消費動向
  • 需要量・販売量(数量ベース)
  • 規制と使用正当化に向けた活動


  • 主要な世界的ブランド
  • 新しい乱用抑制技術
  • パイプライン製品
  • 市場の新たな動向
  • 企業統合戦略


  • 略語/頭文字集
  • 参考資料
Product Code: GBI053CBR


The report provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%).

Their use for medicinal purposes has been highly controversial for several decades. Although recognized as potent painkillers, potential for misuse is high. As a result, all regulatory authorities strive to maintain a fine balance between enforcing strict regulations that will crack down on illicit usage but at the same time ensure accessibility for genuine medical purposes. Amidst concerns regarding inadequate pain management due to low accessibility, there are also concerns regarding a lack of significant clinical evidence of their role in managing chronic pain. However, new abuse-deterrent technologies provide an incentive to prescribe more opioids in pain management by alleviating concerns over misuse potential. The approval of such new drugs and formulations has proved a new impetus to growth in opioid usage in the five major Western European countries.

Opioids are largely used for two medicinal purposes: pain management and substitution treatment for drug dependence. Several of the recently approved and pipeline opioid analgesics have a strong focus on reducing misuse potential, which is one of the most significant barriers to usage in pain management. However, usage is on the rise following the introduction of new abuse-deterrent formulations of fentanyl and oxycodone, and initiatives that aim to rationalize usage in pain management. Demand is also high in substitution treatment. While both methadone and buprenorphine are approved for substitute treatment, buprenorphine usage increased in Europe after the approval of Suboxone in 2006, in combination with naloxone, a pure opioid antagonist that acts as an abuse-deterrent.


The report covers the five major Western European countries (the UK, Germany, France, Italy and Spain) and includes -

  • An overview of opioids in pain management and substitution treatment, and usage constraints for both
  • Brief analysis of recent approvals of key abuse-deterrent drugs and their impact on consumption and market growth
  • Country snapshots, comprising key regulations, consumption, market revenues, market forecasts and key drivers and barriers
  • An overview of new abuse-deterrent technologies and profiles of key pipeline products

Key Reasons to Purchase

  • Gain a perspective of the opioids market size and key drivers and challenges that dictate the market trends in each of the five major countries in Western Europe
  • Gauge the impact of key recently approved abuse-deterrent technologies on opioid usage
  • Develop an understanding of how the regulatory landscape affects market potential and growth in each country
  • Identify the key molecules that are currently the leading players in each region and those that hold the highest potential in the forecast period
  • Scan the pipeline for innovative products with abuse-deterrent technologies that could have an impact on opioid usage in the pain management market

Table of Contents

  • Executive summary
  • Opioids: an overview
    • Opioids in pain management
    • Usage constraints
    • International conventions
  • Drug misuse in Western Europe
    • Extent of drug misuse
    • Impact of abuse-deterrent drugs
    • Key abuse-deterrent products
  • Unmet need in pain management
    • Requirement and consumption
    • Key activities to promote usage
  • Regulatory landscape
    • Finding a balance between accessibility and regulations
  • Opioids market in Europe
    • Consumption trends in Europe
    • Estimated revenue and forecast
  • Country snapshots (UK, Germany, France, Italy, Spain)
    • Regulatory landscape
    • Consumption trends
    • Volume and revenue by molecule
    • Barriers and activities to rationalize usage
  • Market developments
    • Leading global brands
    • New abuse-deterrent technologies
    • Pipeline products
    • New developments
    • Strategic consolidations
  • Appendix
    • Abbreviations/acronyms
    • References
Back to Top